E. Martinenaite

发表

Spontaneous presence of FOXO3-specific T cells in cancer patients

I. Svane, Ö. Met, P. Straten, 2014, Oncoimmunology.

An immunogenic first-in-human immune modulatory vaccine with PD-L1 and PD-L2 peptides is feasible and shows early signs of efficacy in follicular lymphoma

I. Svane, A. O. Gang, Ö. Met, 2021, OncoImmunology.

Peptide vaccination activating Galectin-3-specific T cells offers a novel means to target Galectin-3-expressing cells in the tumor microenvironment

I. Svane, Ö. Met, M. Carretta, 2022, Oncoimmunology.

Cytotoxic T cells isolated from healthy donors and cancer patients kill TGFÎ2-expressing cancer cells in a TGFÎ2-dependent manner

M. Donia, I. Svane, R. Mortensen, 2021 .

Arginase 1–Based Immune Modulatory Vaccines Induce Anticancer Immunity and Synergize with Anti–PD-1 Checkpoint Blockade

M. Iezzi, M. Chapellier, S. Ugel, 2021, Cancer Immunology Research.

Frequent adaptive immune responses against arginase-1

M. Donia, I. Svane, R. Mortensen, 2018, Oncoimmunology.

PD-L1 peptide co-stimulation increases immunogenicity of a dendritic cell-based cancer vaccine

M. Donia, I. Svane, T. Borch, 2016, Oncoimmunology.

Arginase-1-based vaccination against the tumor microenvironment: the identification of an optimal T-cell epitope

I. Svane, M. Andersen, S. M. Ahmad, 2019, Cancer Immunology, Immunotherapy.

MERTK Acts as a Costimulatory Receptor on Human CD8+ T Cells

J. Becker, L. Rasmussen, M. Donia, 2019, Cancer Immunology Research.

CCL22-based peptide vaccines induce anti-cancer immunity by modulating tumor microenvironment

M. Chapellier, M. Andersen, M. Zocca, 2022, Oncoimmunology.

High frequencies of circulating memory T cells specific for calreticulin exon 9 mutations in healthy individuals

I. Svane, H. Hasselbalch, C. Ellervik, 2019, Blood Cancer Journal.

Arginase-1 targeting peptide vaccine in patients with metastatic solid tumors – A phase I trial

I. Svane, E. Ehrnrooth, M. Andersen, 2022, Frontiers in Immunology.

The inhibitory checkpoint, PD-L2, is a target for effector T cells: Novel possibilities for immune therapy

M. Donia, I. Svane, Ö. Met, 2018, Oncoimmunology.

Peptide Vaccination Against PD-L1 With IO103 a Novel Immune Modulatory Vaccine in Multiple Myeloma: A Phase I First-in-Human Trial

L. Olsen, I. Svane, T. Klausen, 2020, Frontiers in Immunology.

Anti-PD-L1/PD-L2 therapeutic vaccination in untreated chronic lymphocytic leukemia patients with unmutated IgHV

I. Svane, Ö. Met, C. Niemann, 2022, Frontiers in Oncology.

Clinical efficacy of T-cell therapy after short-term BRAF-inhibitor priming in patients with checkpoint inhibitor-resistant metastatic melanoma

M. Lauss, M. Donia, K. Harbst, 2021, Journal for ImmunoTherapy of Cancer.

An arginase1- and PD-L1-derived peptide-based vaccine for myeloproliferative neoplasms: A first-in-man clinical trial

I. Svane, H. Hasselbalch, R. Mortensen, 2023, Frontiers in Immunology.

The JAK2V617F mutation is a target for specific T cells in the JAK2V617F-positive myeloproliferative neoplasms

H. Hasselbalch, Ö. Met, P. Straten, 2017, Leukemia.

Cytotoxic T cells isolated from healthy donors and cancer patients kill TGFβ-expressing cancer cells in a TGFβ-dependent manner

M. Donia, I. Svane, R. Mortensen, 2021, Cellular & Molecular Immunology.

A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma

M. Donia, I. Svane, H. Hendel, 2021, Nature Medicine.

A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma

M. Donia, I. Svane, H. Hendel, 2021, Nature Medicine.

CCL22-specific T Cells: Modulating the immunosuppressive tumor microenvironment

M. Donia, I. Svane, T. Klausen, 2016, Oncoimmunology.

TGFβ-derived immune modulatory vaccine: targeting the immunosuppressive and fibrotic tumor microenvironment in a murine model of pancreatic cancer

L. Grøntved, M. Donia, D. H. Madsen, 2022, Journal for ImmunoTherapy of Cancer.

First in man study: Bcl-Xl_42-CAF®09b vaccines in patients with locally advanced prostate cancer

M. Donia, I. Svane, S. Hadrup, 2023, Frontiers in Immunology.

The metabolic enzyme arginase-2 is a potential target for novel immune modulatory vaccines

I. Svane, Ö. Met, M. Carretta, 2020, Oncoimmunology.

The calreticulin (CALR) exon 9 mutations are promising targets for cancer immune therapy

I. Svane, H. Hasselbalch, Ö. Met, 2018, Leukemia.

Peripheral memory T cells specific for Arginase-1

I. Svane, M. Andersen, S. M. Ahmad, 2019, Cellular & Molecular Immunology.

Spontaneous T-cell responses against Arginase-1 in the chronic myeloproliferative neoplasms relative to disease stage and type of driver mutation

H. Hasselbalch, M. Holmström, M. Andersen, 2018, Oncoimmunology.

778 Modulating tumor microenvironment with arginase-1 specific T cells

I. Svane, Ö. Met, M. Holmström, 2021, Journal for ImmunoTherapy of Cancer.

1182 Modulating the tumor microenvironment by a targeting TGFB1 with vaccine-induced immune responses

M. Chapellier, M. Al-Hajj, M. Carretta, 2022, Regular and Young Investigator Award Abstracts.

LBA48 Clinical efficacy and immunity of combination therapy with nivolumab and IDO/PD-L1 peptide vaccine in patients with metastatic melanoma: A phase I/II trial

I. Svane, M. Andersen, E. Martinenaite, 2020 .

Arginase-1 specific CD8+ T cells react toward malignant and regulatory myeloid cells

Ö. Met, P. thor Straten, E. Martinenaite, 2024, Oncoimmunology.